Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the chronic pancreatitis (cp) market grown over the years?

The market size for chronic pancreatitis (CP) has experienced significant growth in the past few years. We expect it to expand from a worth of $4.91 billion in 2024 to $5.25 billion in 2025, showcasing a compound annual growth rate (CAGR) of 6.7%. The surge in this historical phase can be attributed to numerous factors including the escalated prevalence of alcohol use, increasing instances of smoking, genetic vulnerabilities and familial history, burgeoning awareness of pancreatic ailments, a rise in diabetes incidents related to pancreatitis, augmented healthcare expenditure, and enhanced healthcare service accessibility.

What Is the forecasted market size and growth rate for the chronic pancreatitis (cp) market?

The market for chronic pancreatitis (CP) is set to experience significant growth in the forthcoming years, reaching a valuation of $6.72 billion by 2029 at a compound annual growth rate (CAGR) of 6.4%. Several factors are poised to contribute to this growth during the forecast period, including an aging population, escalated demand for enzyme replacement therapies, an increasing emphasis on early diagnosis, growth of the healthcare sector in burgeoning markets, breakthroughs in pain management therapies, and ongoing research and clinical trials in the field of pancreatitis treatment. Key trends to watch out for during the forecast period consist of the incorporation of artificial intelligence into diagnostic imaging, the advent of minimally invasive surgery, wearable technology for ongoing health tracking, next-generation sequencing geared towards genetic testing, the use of machine learning in tracking disease progression, and the emergence of advanced diagnostic tools.

Get your chronic pancreatitis (cp) market report here!

https://www.thebusinessresearchcompany.com/report/chronic-pancreatitis-cp-global-market-report

What are the major factors driving growth in the chronic pancreatitis (cp) market?

The escalating intake of alcohol is anticipated to spur the expansion of the chronic pancreatitis market in the foreseeable future. The term alcohol consumption is typically associated with the drinking of liquors that contain ethanol, often with the goal of relaxation, socialization, or cultural observance. However, when done in excess, it can lead to addiction or severe health issues. The surge in alcohol consumption can be attributed to factors such as growing societal approval, urban development, lifestyle modification, and practices for managing stress, particularly among younger demographics. Over time, consuming alcohol can lead to chronic pancreatitis by instigating inflammation and harm to the cells of the pancreas, eventually leading to conditions such as fibrosis, obstruction in the ducts, and lasting dysfunction due to toxic metabolic waste products. For instance, a report by the Kirin Holdings Company Limited, a Japan-based beer and beverage enterprise, stated in December 2023 that the global beer consumption in 2022 witnessed a rise of approximately 5.4 million kiloliters (equivalent to around 8.5 billion 633ml bottles) from 2021, reaching roughly 192.1 million kiloliters. This growth of 2.9% has been credited to the relaxation of the COVID-19’s influence, equaling around 303.5 billion 633ml bottles. As a result, the escalating intake of alcohol is a significant contributor to the expansion of the chronic pancreatitis market.

What key areas define the segmentation of the global chronic pancreatitis (cp) Market?

The chronic pancreatitis (CP) market covered in this report is segmented –

1) By Treatment: Analgesic, Artificial Digestive Enzyme, Protein Supplements, Steroids, Antibiotics, Other Treatments

2) By Diagnosis: Computed Tomography (CT) Scan, Magnetic Resonance Cholangiopancreatography, Ultrasound Sonography, Other Diagnosis

3) By Route Of Administration: Oral, Parenteral

4) By End User: Hospitals, Homecare, Other End Users

Subsegments:

1) By Analgesic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Opioids

2) By Artificial Digestive Enzyme: Pancrelipase, Pancreatin

3) By Protein Supplements: Branched-Chain Amino Acids (BCAA), Whey Protein

4) By Steroids: Prednisone, Dexamethasone

5) By Antibiotics: Ciprofloxacin, Metronidazole

6) By Other Treatments: Endoscopic Treatment, Surgery

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21146&type=smp

What are the top market players propelling the growth of the chronic pancreatitis (cp) industry?

Major companies operating in the chronic pancreatitis (CP) market are Pfizer, Johnson & Johnson, Merck & Co Inc, AbbVie Inc, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Baxter, CSL Behring, Octapharma AG, Dr. Reddy’s Laboratories, Nestle Health Science, Cerata Pharmaceuticals, Unichem Laboratories Ltd, LGM Pharma, Aptalis Pharmaceutical Technologies, Digestive Care Inc, Akron Biotech

What emerging trends are influencing the growth of the chronic pancreatitis (cp) market?

Leading firms in the chronic pancreatitis market are investing in the creation of innovative technologies, like enzyme replacement therapy, to manage exocrine pancreatic insufficiency (EPI), a condition often linked with chronic pancreatitis. This therapy entails the intake of orally administered pancreatic enzymes to support digestion in individuals with inadequate pancreatic function. For instance, First Wave BioPharma Inc, a clinical-stage biopharmaceutical company from the US, revealed the findings of the Phase 2 SPAN clinical trial in July 2023, focusing on an advanced enteric microgranule delivery formulation of adrulipase for EPI treatment in patients suffering from cystic fibrosis (CF) and chronic pancreatitis. Adrulipase, a recombinant lipase enzyme originating from the Yarrowia lipolytica yeast, is given orally in the form of a non-systemic biological capsule intended to disintegrate fat molecules in the digestive tract of EPI patients, thus facilitating their absorption as nutrients.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21146

What regions are dominating the chronic pancreatitis (cp) market growth?

North America was the largest region in the chronic pancreatitis (CP) market in 2024. The regions covered in the chronic pancreatitis (cp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Autologous Cell Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autologous-cell-therapy-global-market-report

Stem Cell Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/stem-cells-therapy-global-market-report

Mycoplasma Testing Global Market Report 2025

https://thebusinessresearchcompany.com/report/mycoplasma-testing-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: